WASHINGTON, Jan. 21 /PRNewswire-USNewswire/ -- Nancy L. Buc, a partner
in the law firm of Buc & Beardsley in Washington, D.C., has been elected
Chair of the Board of Directors of the Food and Drug Law Institute, the
leading non-profit association comprised of food and drug attorneys and
manufacturers.
In addition, William B. Schultz, a partner in the law firm of Zuckerman
Spaeder in Washington, D.C. was elected vice chair and Linda Suydam, D.
Pa., President and CEO of Consumer Healthcare Products Association was
chosen Treasurer.
The Board of Directors also selected the following new members: Minnie
V. Baylor-Henry, Vice President for Medical & Regulatory Affairs for McNeil
Consumer & Specialty Pharmaceuticals (McNeil), a Johnson & Johnson Company;
Mark S. Frankel, Ph.D., Director of the Program on Scientific Freedom,
Responsibility and Law at the American Association for the Advancement of
Science (AAAS); Christopher L. Hagenbush, a Partner in the law firm of
Patton Boggs LLP, Washington, DC.; Ralph F. Hall, Counsel in the law firm
of Baker & Daniels, Indianapolis, IN., and Visiting Professor at the
University of Minnesota School of Law; and John M. Taylor III, Executive
Vice President, Health for the Biotechnology Industry Organization (BIO).
"We are very pleased that Ms. Buc will be serving as our new chair,"
said FDLI President and CEO James J Kelly. "Her experience at FDA and in
food and drug law generally is invaluable to our mission to be on the
cutting edge of the relationship between science and food and drug law,
regulation and policy. We look forward to working with her and all the new
officers and members of the Board," he added.
Buc previously served as General Counsel for the Food and Drug
Administration (FDA) from 1980-1981. During an earlier period of government
service, she served as Attorney-Advisor to the Chairman of the Federal
Trade Commission and Assistant Director of that agency's Bureau of Consumer
Protection. A member of the Institute of Medicine's Committee on
Contraceptive Research and Development, she also was a member of the
National Institutes of Health's Recombinant DNA Advisory Committee and its
Consensus Panel on Effective Medical Treatment of Herion Addiction. Buc is
also an Adjunct Professor of Law at Georgetown University Law Center. She
is a Director of the National Partnership for Women and Families, and was
formerly a director of Agritope, Inc. Buc is a graduate of Brown University
and the University of Virginia School of Law.
Prior to joining Zuckerman Spaeder, Schultz held the position of Deputy
Assistant Attorney General, Civil Division, at the U.S. Department of
Justice. He supervised the Civil Division's Appellate Litigation and the
Department's lawsuit against the tobacco industry. He also served as Deputy
Commissioner for Policy at the Food and Drug Administration (1994-1998) and
as Counsel for the Subcommittee on Health and the Environment, U.S. House
of Representatives, Committee on Energy and Commerce (1990-1994).
Suydam was formerly the Senior Associate Commissioner, Office of the
Commissioner, at FDA. She was responsible for the development and
implementation of processes to implement change and develop new regulatory
strategies for FDA to efficiently and effectively operate within a global
economy.
At McNeil, Baylor-Henry is directly responsible for the oversight of
the Divisions of Regulatory Affairs, Medical Education, Outcomes Research,
Investigator-Initiated Studies, Medical Science Liaisons, and Medical
Information & Communications.
Frankel is staff officer for the AAAS Committee on Scientific Freedom
and Responsibility and the AAAS-American Bar Association National
Conference of Lawyers and Scientists, and editor of the quarterly
publication, Professional Ethics Report.
Before joining Patton Boggs, Hagenbush worked as in-house counsel for
the Coca-Cola Company. He represented the company's interests before FDA
and the Federal Trade Commission in addition to self-regulatory,
international and supra-national regulatory bodies, plus trade
associations, NGOs and other non-profit organizations.
Hall has experience in the design and implementation of regulatory
compliance programs, with FDA enforcement actions, in managing complex
patent litigation and licensing matters, and in general corporate
counseling. Prior to rejoining Baker & Daniels, he was with Guidant
Corporation where he served as Senior Vice President and Deputy General
Counsel, Litigation and Compliance.
Taylor previously served as Divisional Vice President, Government
Affairs, with Abbott Laboratories. He was formerly the Associate
Commissioner for Regulatory Affairs at FDA and Director of the Office of
Enforcement, Office of Regulatory Affairs (ORA) at FDA.
Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food
and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and
dozens of books and publications for attorneys, regulatory affairs
practitioners, scientists, health care professionals, government employees
and marketers in the food and drug field. For more information, visit
http://www.fdli.org.
SOURCE Food and Drug Law Institute
 back to top
Related links:
http://www.fdli.org
CONTACT:
Michael Levin-Epstein, Editor-in-Chief of the
Food and Drug Law Institute, +1-202-222-0897, mdl@fdli.org
|
